Helsinn Healthcare SA
Retroactive, March 20th, 2018, Helsinn acquired worldwide rights to Valchlor/Ledaga, an alkalyting agent for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) from Actelion Pharmaceuticals Ltd.
More details in this link.